SCHEDULE: Sirenia Capital Management Reports 5% Stake in AnaptysBio

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 5.0% of AnaptysBio, Inc. common stock as of June 30, 2026.

Summary

• Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, indicating their beneficial ownership of 1,491,959 shares of AnaptysBio, Inc. common stock.
• This holding represents 5.0% of the outstanding common stock as of June 22, 2026.
• The filing is an amendment (Amendment No. 1) and the event date requiring the filing is June 30, 2026.
• Sirenia Capital Management LP is a Delaware limited partnership, and Alex Silverstein is a United States citizen and the managing member of Sirenia Capital Management GP LLC.
• The shares are held within a managed account by Sirenia Capital Management LP.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership to a threshold that does not indicate aggressive action or significant concern.

Positives

• Reporting a significant ownership stake can sometimes indicate confidence in the company's future prospects by an investment firm.
• The filing is routine and does not suggest any immediate hostile intent, which is generally viewed positively by the market.

Negatives

• The filing does not provide any specific positive financial or operational updates from AnaptysBio, Inc. itself, only ownership information.
• The reporting persons have shared voting and dispositive power, which can sometimes lead to less direct control or decision-making compared to sole power.

Risks

• While not explicitly stated as a risk in this filing, any significant shift in major shareholder holdings can introduce uncertainty.
• The filing does not detail specific risks related to AnaptysBio's business operations or financial health.

Future Outlook

This filing does not contain forward-looking statements or guidance from AnaptysBio, Inc. It solely reports on beneficial ownership.

Management Comments

• The filing states: 'The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.'
• The filing also includes a certification: 'By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.'

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing the 5% beneficial ownership threshold. This filing indicates Sirenia Capital Management's investment activity in the biotechnology sector, specifically in AnaptysBio, Inc.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest or a change in the shareholder base, which could influence market perception.
• Management of AnaptysBio: The company's management will be aware of the significant stake held by Sirenia Capital Management.

Next Steps

• Sirenia Capital Management LP and Alex Silverstein will continue to hold their shares in AnaptysBio, Inc.
• Further filings may be required if their beneficial ownership changes significantly.

Key Dates

Keywords

AnaptysBio, Schedule 13G, Sirenia Capital Management, Alex Silverstein, Beneficial Ownership, Investment Management, Shareholder